Phaseline

Companies › Hangzhou GluBio Pharmaceutical

Hangzhou GluBio Pharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GLB-001–Phase 1Polycythemia VeraDec 2026
GLB-002–Phase 1Non-Hodgkin LymphomaFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06378437GLB-001Phase 1Polycythemia VeraOncologyDec 2026
NCT06219356GLB-002Phase 1Non-Hodgkin LymphomaOncologyFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.